Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report

PURPOSE: In National Wilms Tumor Study 5 (NWTS-5), tumor-specific combined loss of heterozygosity of chromosomes 1p and 16q (LOH1p/16q) was associated with adverse outcomes in patients with favorable histology Wilms tumor. The AREN0533/AREN0532 studies assessed whether augmenting therapy improved ev...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Dix, David B., Fernandez, Conrad V., Chi, Yueh-Yun, Mullen, Elizabeth A., Geller, James I., Gratias, Eric J., Khanna, Geetika, Kalapurakal, John A., Perlman, Elizabeth J., Seibel, Nita L., Ehrlich, Peter F., Malogolowkin, Marcio, Anderson, James, Gastier-Foster, Julie, Shamberger, Robert C., Kim, Yeonil, Grundy, Paul E., Dome, Jeffrey S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2019
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001789/
https://ncbi.nlm.nih.gov/pubmed/31449468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01972
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller